| Trial ID: | L4284 |
| Source ID: | NCT02650596
|
| Associated Drug: |
Glp-1
|
| Title: |
Effects of GLP-1 on Chronic Heart Failure
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Heart Failure
|
| Interventions: |
DRUG: GLP-1|DRUG: Placebo
|
| Outcome Measures: |
Primary: left ventricular ejection fraction measured by 3D echocardiography, The primary efficacy endpoint was the effect of liraglutide on left ventricular ejection fractions (LVEF) measured by 3D echocardiography at 3 months., 3 months | Secondary: plasma NT-proBNP levels, a change in plasma NT-proBNP levels at 3 months after treatment, 3 months|a change in 6-minute walk distance, The change in 6-minute walk distance at 3 months after treatment., 3 months|differences in the incidences of treatment-emergent adverse events, differences in the incidences of treatment-emergent adverse events at 3 months, 3 months
|
| Sponsor/Collaborators: |
Sponsor: Shi Yang
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
68
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2016-01
|
| Completion Date: |
2018-02
|
| Results First Posted: |
|
| Last Update Posted: |
2016-01-08
|
| Locations: |
PLA General Hospital, Beijing, Beijing, 100853, China
|
| URL: |
https://clinicaltrials.gov/show/NCT02650596
|
